Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees enough in the data to pursue further development in a severe form of asthma and it wants to talk with regulators about advancing the compound to a larger Phase 3 study. The Gossamer … Continue reading “Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma”
Category: San Diego
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
It’s October: a time of days growing shorter, leaves changing color, and phone calls in the wee hours that rouse scientists from slumber notifying them they’ve won the highest honor in their fields. This week, the 2020 Nobel Prize in physiology or medicine was awarded to Harvey Alter, Michael Alton, and Charles Rice, whose research … Continue reading “Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More”
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug
Arrowhead Pharmaceuticals’ gene silencing treatment for a rare liver disease will move through the regulatory process and potential commercialization with the muscle of Takeda Pharmaceutical behind it. Takeda (NYSE: [[ticker:TAK]]) has agreed to pay $300 million up front in a partnership on Arrowhead (NASDAQ: [[ticker:ARWR]]) drug ARO-AAT as a treatment for alpha-1 antitrypsin-associated liver disease. … Continue reading “In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug”
BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting
Science is the way out of this pandemic—and scientific breakthroughs are on the ballot on November 3. To help you get ready for Election Day, BIO’s initiative Biotech Votes has resources to help you get registered and get informed. First, make sure you’re registered to vote. Check out this handy form to verify your voter … Continue reading “BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting”
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
Amid the bombast of Tuesday’s presidential debate, viewers caught some discussion about the response to the coronavirus pandemic and efforts to develop a COVID-19 vaccine. In the crosstalk, the president made an unsupported claim that we are weeks away from having vaccines. It’s true that some pharmaceutical companies are already manufacturing their COVID-19 vaccine candidates … Continue reading “Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More”
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug
Ovid Therapeutics and Takeda Pharmaceutical joined forces three years ago to develop a small molecule into a potential epilepsy drug. That research is starting to pay off as the companies now look ahead to pivotal studies testing that compound in several inherited forms of the disorder. On Wednesday, New York-based Ovid (NASDAQ: [[ticker:OVID]]) reported Phase … Continue reading “With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug”
Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward
Had things turned out differently, scientists at Galecto might be watching their idiopathic pulmonary fibrosis drug candidate develop in the hands of a big pharmaceutical company. But Bristol Myers Squibb passed on its option to acquire Galecto leaving the biotech to forge ahead on its own. Now the company has $64 million to advance clinical … Continue reading “Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward”
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More
In biotech, you can go home again. Four years ago, Illumina spun out cancer diagnostics startup Grail. This week, the gene sequencing giant announced it is acquiring Grail in an $8 billion cash and stock deal. Grail set out with the goal of developing a diagnostic test that detects cancer from the genetic snippets tumors … Continue reading “Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More”
Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders
Amyotrophic lateral sclerosis (ALS) has no cure and few available treatments but the past decade has revealed new knowledge about the pathology of the disease. Libra Therapeutics is turning that research into potential therapies, and it now has $29 million to advance its work. While the exact causes of many neurological disorders are unknown, Libra … Continue reading “Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders”
Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week
The 2020 National Xconomy Awards complimentary two-week, 11-part, on-demand Meet the Finalists daily webcast series continues this Tuesday and Wednesday at 11 a.m. ET. Registration is complimentary and includes access to a networking app with already more than 600 life science contacts. The daily series leads up to the Thursday, Sept. 24 free online National Xconomy Awards … Continue reading “Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week”
Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal
[Updated, 3:45 pm ET.] Grail is set to be acquired for $8 billion by Illumina, the gene sequencing giant that formed the cancer diagnostics developer and spun it out as a separate company four years ago. The announcement comes less than two weeks after Menlo Park, CA-based Grail revealed its plans for an IPO to … Continue reading “Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal”
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
Gilead Sciences CEO Daniel O’Day has spoken openly about acquisitions as a way to build up the company’s drug pipeline. This week, it made its biggest buy yet. The $21 billion Immunomedics acquisition brings to Gilead a cancer drug that many analysts project will become a blockbuster seller. Some of those analysts think Gilead might … Continue reading “Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More”
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
Dyne Therapeutics, a company developing genetic medicines for rare muscular disorders, has raised $233 million in an IPO that topped the preclinical-stage biotech’s projections. Late Wednesday, Dyne priced its offering of about 12.3 million shares at $19 each. The Waltham, MA-based biotech had previously planned to sell 10.3 million shares in the range of $16 … Continue reading “Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D”
Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series
The Xcelerate Keynote Series has added Moderna CMO Tal Zaks to the expert lineup of speakers set to present next Monday, Sept. 21. As you likely know, Moderna is one of the front-runners in the COVID-19 vaccine race, and we look forward to adding his insight to a packed agenda focused on innovative solutions during … Continue reading “Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series”
Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston
Presented by Xconomy, the online Xcelerate Keynote Series at Biotech Week Boston on Monday, Sept. 21 places a spotlight on life science leaders who are breaking new ground with methods and solutions in R&D, planning, and production that are improving patient outcomes. As the industry navigates uncertainty, the keynote speakers will help drive your business … Continue reading “Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston”
Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More
COVID-19 research efforts are often characterized as a race between companies, a description that reflects the urgency to develop a vaccine for the novel coronavirus. The description is not quite right. A race has one winner and public health officials have said we’ll need multiple vaccines to address the global need. Vaccine developers have progressed … Continue reading “Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More”
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
Labor Day is just around the corner and many people are looking forward to a last chance to celebrate the waning days of summer. But ahead of the holiday weekend, biopharmaceutical companies were hard at work closing deals. Food conglomerate Nestlé is delving deeper into pharmaceuticals with its $2.6 billion deal to acquire Aimmune Therapeutics, … Continue reading “Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More”
Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs
If Lumen Bioscience achieves its goals, patients will be able to take its drugs the same way some people supplement breakfast: a spoonful heaped onto a bowl of cereal or mixed into juice. The startup harnesses spirulina, protein-rich cyanobacteria touted by many health enthusiasts as a “superfood.” Lumen CEO Brian Finrow (pictured above, right) acknowledges … Continue reading “Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs”
Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday
Don’t miss out on savings for this year’s online Xcelerate Keynote Series at Biotech Week Boston – our early bird sale ends this Friday! Speakers include: Jeff Baker – Deputy Director, Office of Biotechnology Products, FDA Michelle McMurry-Heath – President & CEO, BIO John Maraganore – CEO, Alnylam Pharmaceuticals Yvonne Greenstreet – Chief Operating Officer, Alnylam Pharmaceuticals Andrew Plump … Continue reading “Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday”
Akcea Therapeutics Is Returning to Parent Ionis Pharma in $500M Buyout
[Updated 9/1/2020, 7:58 a.m. See below.] Akcea Therapeutics is returning to its parent company, Ionis Pharmaceuticals, in a $500 million deal that brings an end to a tumultuous three years as a standalone company. The definitive agreement announced Monday calls for Carlsbad, CA-based Ionis (NASDAQ: [[ticker:IONS]]) to pay $18.15 for each share of Akcea (NASDAQ: … Continue reading “Akcea Therapeutics Is Returning to Parent Ionis Pharma in $500M Buyout”
Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More
Among the casualties of the COVID-19 pandemic: the credibility of government agencies entrusted with protecting public health. The FDA this week granted emergency use authorization for convalescent plasma as a treatment for infection by the novel coronavirus. FDA Commissioner Stephen Hahn and Department of Health and Human Services Secretary Alez Azar both misrepresented the magnitude … Continue reading “Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More”
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
Not long ago, having early data about how an experimental drug worked in humans was expected of biotechs considering IPOs. Dyne Therapeutics may not reach human testing until 2022, but, like many of its preclinical peers this year, the company is choosing to jump into public markets now while investor interest in the biotech sector … Continue reading “Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases”
Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout
Acadia Pharmaceuticals has acquired Texas biotech CerSci Therapeutics, a privately held company with a clinical-stage molecule under evaluation as a potential therapy for post-surgical and nerve pain. The San Diego-based company splashed out $52.5 million on the buyout, a cash-and-stock deal—$47.2 million of it in Acadia shares, according to a regulatory filing—that closed Monday. Acadia … Continue reading “Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout”
Kura Oncology Adds Kyowa Kirin’s Stephen Dale as Chief Medical Officer
Stephen Dale has joined Kura Oncology (NASDAQ: [[ticker:KURA]]) as its chief medical officer. He was most recently global head of medical science, with a primary focus in oncology, at Kyowa Kirin. Prior he held various roles at AstraZeneca (NYSE: [[ticker:AZN]]), including clinical head of oncology. The CMO role at Kura was previously held by company … Continue reading “Kura Oncology Adds Kyowa Kirin’s Stephen Dale as Chief Medical Officer”
FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines
The FDA has authorized the use of plasma from people who have recovered from infection by the novel coronavirus as a treatment for hospitalized COVID-19 patients, a move widely perceived as influenced by political pressure given the lack of clear evidence of clinical benefit. Treating patients with plasma—the water, salts, and proteins that make up … Continue reading “FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines”
Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More
While business is historically slow in August, this month seems to be bucking the trend, just like so many other unexpected developments in 2020. Perhaps life sciences executives have been less distracted by summer excursions this year in a world in which the COVID-19 pandemic has significantly curtailed travel. This week two pharmaceutical companies announced … Continue reading “Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More”
Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts
Two biotechs this week topped the $100 million mark in their respective initial public offerings, both of which were able to offer more shares than planned. One, a company with nearly nine month’s-worth of revenue from a newly commercialized drug and the other, an early-clinical stage oncology drug developer, illustrate the range of biotech companies … Continue reading “Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts”
Fate Therapeutics Taps Celgene’s Dulac as Its Chief Financial Officer
Edward Dulac has joined Fate Therapeutics (NASDAQ: [[ticker:FATE]]) as its chief financial officer. Dulac was most recently vice president of business development and strategy at Celgene, which is now part of Bristol Myers Squibb. His prior experience includes serving as a biopharma equity research analyst at Barclays Capital and at Lehman Brothers and in corporate … Continue reading “Fate Therapeutics Taps Celgene’s Dulac as Its Chief Financial Officer”
Sorrento Therapeutics Cuts Ties With Chief Financial Officer Jiong Shao
Sorrento Therapeutics (NASDAQ: [[ticker:SRNE]]) has fired its chief financial officer, Jiong Shao, according to a regulatory filing. The San Diego-based company, which is among the biotechs developing potential COVID-19 treatments and tests, didn’t explain why. Sorrento appointed Najjam Asghar, its chief accounting officer, to handle CFO responsibilities as well until the firm finds a successor. … Continue reading “Sorrento Therapeutics Cuts Ties With Chief Financial Officer Jiong Shao”
Patient Death in Poseida Prostate Cancer Study Prompts Clinical Hold
A Phase 1 trial testing a Poseida Therapeutics cell therapy in men with prostate cancer is on hold after a patient enrolled in the study died of liver failure nearly three weeks after receiving the treatment. The San Diego company, which has touted its product candidates as safer than early-generation versions developed by other companies, … Continue reading “Patient Death in Poseida Prostate Cancer Study Prompts Clinical Hold”
Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More
The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work. Four years after its microbiome therapy failed in a mid-stage study, the company reported early positive data from a pivotal test of its treatment for a type of gut infection. The results are … Continue reading “Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More”
Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup
Ligand Pharmaceuticals plans to acquire recombinant protein therapeutics maker Pfenex for $438 million, the companies announced Monday. The larger company agreed to pay $12 per share for Pfenex (NYSE American: [[ticker:PFNX]])—a 57 percent premium to its closing price Monday. San Diego-based Ligand (NASDAQ: [[ticker:LGND]]) generates revenue from licensing deals and royalties paid by pharmaceutical companies … Continue reading “Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup”
Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy
Bayer has been building up its women’s health drug pipeline by striking deals and on Tuesday the pharmaceutical giant unveiled its latest one: $425 million up front for KaNDy Therapeutics, a biotech whose experimental menopause drug is projected as a blockbuster seller. KaNDy’s small molecule drug, NT-814, is in development as a treatment for common … Continue reading “Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy”
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More
The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development and a slew of biotechs are testing compounds, previously intended for a wide range of indications, as potential COVID-19 treatments. This week saw another major development brought on by industry efforts to adjust to … Continue reading “Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More”
Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds
Denali Therapeutics has selected a brain-penetrating Parkinson’s disease drug candidate to advance to late-stage testing, and Biogen is paying $1 billion to kick off a partnership on that compound and potentially others. According to terms of the deal announced Thursday, the companies will co-develop the small molecule, dubbed DNL151. Biogen (NASDAQ: [[ticker:BIIB]]) also gains options … Continue reading “Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds”
Aspen Neuroscience Chief Scientific Officer Loring to Step Down
Jeanne Loring, a co-founder of Aspen Neuroscience, is stepping down from her role as its chief scientific officer. The La Jolla, CA-based company said Loring—professor emeritus at the Scripps Research Institute, where her work on the genomics of induced pluripotent stem cells laid the foundation for the company’s launch—will become a special advisor to the … Continue reading “Aspen Neuroscience Chief Scientific Officer Loring to Step Down”
Prometheus Taps Conatus’s Marshall as Its Chief Financial Officer
Prometheus Biosciences has appointed Keith Marshall its chief financial officer. Marshall most recently served as chief operating officer and CFO at Conatus Pharmaceuticals, which earlier this year merged with Histogen (NASDAQ: [[ticker:HSTO]]). Before Conatus, Marshall was CFO and head of corporate development at Flagship Pioneering spinout Torque Therapeutics, since renamed Repertoire Immune Medicines. Marshall started … Continue reading “Prometheus Taps Conatus’s Marshall as Its Chief Financial Officer”
AnaptysBio Appoints Paul Lizzul as Its Chief Medical Officer
Paul Lizzul has joined AnaptysBio (NASDAQ: [[ticker:ANAB]]) as the company’s chief medical officer. He succeeds Marco Londei, who held the roles of CMO and chief development officer at AnaptysBio until earlier this year, when he joined Dutch biotech Gadeta as CEO. Lizzul most recently served a short stint at Amgen (NASDAQ: [[ticker:AMGN]]) as global development … Continue reading “AnaptysBio Appoints Paul Lizzul as Its Chief Medical Officer”
Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More
The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II. If you’ve never heard of Arya (NASDAQ: [[ticker:ARYBU]]), it’s a shell company that Perceptive Advisors … Continue reading “Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More”
Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort
Public investors are betting big on biotechs, and Inhibrx is looking to capitalize on the industry’s recent resurgence of initial public offerings. The La Jolla, CA-based company, which is developing drugs for cancer and a rare respiratory disease, has again applied for a listing on the Nasdaq, a filing that comes more than a year … Continue reading “Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort”
Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test
Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study. Many cancers grow silently, and once malignant cells are discovered a patient’s prognosis … Continue reading “Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test”
Telehealth Firm AristaMD Adds $24M to Link Primary Docs With Specialists
Telemedicine isn’t just another way to connect patients with doctors. AristaMD has carved out a niche in connecting doctors with, well, other doctors. The San Diego-based telehealth company’s software links primary care physicians and medical specialists through virtual consultations, communication that is intended to reduce healthcare costs by slimming down the number of referrals made … Continue reading “Telehealth Firm AristaMD Adds $24M to Link Primary Docs With Specialists”
Avidity Biosciences Appoints Alnylam’s Jae Kim as Chief Medical Officer
Avidity Biosciences (NASDAQ: [[ticker:RNA]]) has added Jae Kim to its C-suite as chief medical officer. Kim most recently served as vice president of clinical development at Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]). His prior experience includes roles at MyoKardia (NASDAQ: [[ticker:MYOK]]) and Amgen (NASDAQ: [[ticker:AMGN]]). San Diego-based Avidity, which raised a $100 million Series C financing round … Continue reading “Avidity Biosciences Appoints Alnylam’s Jae Kim as Chief Medical Officer”
Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More
EQRx launched in January during the JP Morgan Healthcare Conference with an audacious pledge to create 10 new drugs in as many years and then sell them at “dramatically” lower prices than existing medicines. But it offered few specifics about how it would achieve those goals. This week, drug licensing deals it made with two … Continue reading “Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More”
Acadia Halts Work on Depression Drug After Late-Stage Trial Failure
Acadia Pharmaceuticals received the FDA’s OK for pimavanserin (Nuplazid), the first drug approved to treat hallucinations and delusions associated with Parkinson’s disease, in 2016. Since then, the San Diego company has looked to expand its use into other indications, with mixed results. That trend continued Monday when Acadia (NASDAQ: [[ticker:ACAD]]) reported it would end its … Continue reading “Acadia Halts Work on Depression Drug After Late-Stage Trial Failure”
Exalys Launches With $15M to Treat Postoperative Delirium & More
Venture capitalists like nothing more than pattern matching, and Domain Associates has identified one it especially prefers: licensing drug candidates from a Japanese biopharma and setting up a US company to move it through testing until Big Pharma starts nosing around. It’s a roadmap the VC firm, which has offices in San Diego and Princeton, … Continue reading “Exalys Launches With $15M to Treat Postoperative Delirium & More”
Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More
If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook. This week … Continue reading “Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More”
Last Chance for Xconomy Awards Nominations – Deadline is Friday, July 17
Have you had your say yet? The 2020 National Xconomy Awards represent the very best our life science industry has to offer. It is our privilege to recognize emerging companies and technologies, highlight groundbreaking business collaborations and strategies, celebrate corporate responsibility and diversity, and promote the innovation that delivers new therapeutics and better health to all. Finalists … Continue reading “Last Chance for Xconomy Awards Nominations – Deadline is Friday, July 17”
After Biologic COVID-19 Drug OK’d in India, Equillium Plans a US Test
The drug that Equillium licensed from India-based pharma giant Biocon has received authorization for emergency use in that country in patients hospitalized with COVID-19. The treatment, itolizumab, reduced mortality in a 30-person open-label randomized controlled trial in which the goal was to avoid or address a dangerous inflammatory response to the virus called cytokine release … Continue reading “After Biologic COVID-19 Drug OK’d in India, Equillium Plans a US Test”
Turning Point Names Centrexion’s Partridge as Chief Commercial Officer
Turning Point Therapeutics (NASDAQ: [[ticker:TPTX]]) appointed Andrew Partridge as executive vice president and chief commercial officer. Partridge most recently served as chief operating officer and CCO at privately held Centrexion Therapeutics, a Boston company developing treatments for chronic pain. Previously he was with Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]), where he ended a five-year stint as senior … Continue reading “Turning Point Names Centrexion’s Partridge as Chief Commercial Officer”